

Analysis of Allosterism in Functional Assays ^a

Frederick J. Ehlert

Department of Pharmacology

College of Medicine

University of California, Irvine

Irvine, California 92697-4625

Running title: Analysis of allosterism

To whom correspondence should be addressed:

Frederick J. Ehlert, Ph.D.

Department of Pharmacology

University of California, Irvine

Irvine, California 92697-4625

Tel: 949-824-3709

FAX: 949-824-4855

e-mail: fjehlert@uci.edu

Number of text pages: 27

Number of tables: 5

Number of figures: 9

Number of references: 22

Number of words in *Abstract*: 232

Number of words in *Introduction*: 641

Number of words in *Discussion*: 1412

Abbreviations: α , cooperative effect of the allosteric modulator on agonist affinity; β , cooperative effect of the allosteric modulator on agonist efficacy; BM-5, N-(4-pyrrolidino-2-butynyl)-N-methylacetamide; EC_{50} , concentration of agonist eliciting half-maximal response; E_{max} , maximal response; γ , ratio of β/α ; K_A , dissociation constant of allosteric modulator; K_X , dissociation constant of agonist; RA , relative activity of the agonist in the presence of the allosteric modulator.

Section assignment: Cellular and Molecular

ABSTRACT

The theoretical basis for analyzing the effects of an allosteric modulator on the response to an agonist is described. The effects of an allosteric modulator on the concentration-response curve to an agonist can be attributed to changes in the observed dissociation constant and intrinsic efficacy of the agonist-receptor complex. Each of these two changes can be represented by a coefficient or factor. It is possible to estimate the ratio of the coefficient of change in agonist efficacy divided by that for the agonist dissociation constant. This ratio is designated as the relative activity of the agonist in the presence of the allosteric modulator (RA). The RA value can be estimated for each concentration of allosteric modulator by nonlinear regression analysis, regardless of the shape of the concentration-response curve. Regression analysis of the RA values against the concentration of allosteric modulator yields estimates of the dissociation constant (K_A) of the allosteric modulator and the maximal RA value. If the concentration-response curve to the agonist obeys a logistic function and the allosteric modulator influences the maximal response, it is possible to distinguish between the maximal change in affinity from that of efficacy. If the agonist concentration-response curve obeys a logistic equation with a Hill slope of one, the RA values can be estimated easily from the agonist EC_{50} and E_{max} values. This analysis illustrates the utility of the RA value in quantifying allosteric effects.

INTRODUCTION

Drugs that act allosterically to modify receptor function have unique advantages over those that bind directly to the primary recognition site of a receptor. The latter agents produce a continuous effect, whereas allosteric drugs only tune up or tune down signaling when the endogenous neurotransmitter is released (Burgen, 1981; Ehlert, 1986; Christopoulos, 2002). Thus, allosteric drugs preserve the temporal pattern of signaling across the synapse or neuroeffector junction. Also, with overdose, high concentrations of a directly acting agonist or antagonist can cause excessive receptor activation or inhibition, whereas the maximal effect of an allosteric drug has a ceiling depending upon the nature of its allosteric effect. Thus, protection against overdose can be achieved with allosteric drugs.

There are three pharmacodynamic properties that determine the effects of an allosteric drug on the action of an agonist or endogenous neurotransmitter. These properties are 1) the affinity (K_D) of the allosteric drug for its site on the receptor, 2) its modulatory effect on the affinity of the agonist-receptor complex (cooperativity), and 3) its modulatory effect on the intrinsic efficacy of the agonist-receptor complex. Several investigators have described methods for measuring the affinities and cooperative effects of allosteric drugs in radioligand binding assays (Stockton et al., 1983; Ehlert, 1988a; Lazareno and Birdsall, 1995). However, to date, there have been few attempts to discriminate between allosteric effects on agonist affinity and intrinsic efficacy in functional assays. Moreover, it is often assumed that the methods presently available for investigating allosterism in functional assays are valid only if the allosteric agent is without effect on the intrinsic efficacy of the agonist-receptor complex. However, a null method (Ehlert, 1988a) was described quite some time ago for estimating allosteric ligand affinities in functional assays under conditions where the allosteric agent modulates either the affinity or intrinsic efficacy of the agonist or both. The method was based on the assumption that the intrinsic efficacy of the agonist-receptor-allosteric drug complex (XRA) could be different from that of the agonist-receptor complex (XR). By deriving the mathematical equation for the


combined stimulus elicited by both receptor complexes (i.e., XR and XRA), it was possible rearrange the latter equation to derive a null equation for comparing equivalent tissue responses in the presence and absence of an allosteric drug (Ehlert, 1988a). In the prior report, simple methods for applying the null equation to evaluate allosteric changes in agonist affinity and efficacy were described for highly efficacious agonists exhibiting a large receptor reserve or for situations with little receptor reserve only involving a change in affinity. In principle, it should be possible to apply these mathematics to all conditions using nonlinear regression analysis.

In the present report, the theory for investigating allosteric interactions in functional assays is described. This theory is applied to predict the behavior of the concentration-response curve of an agonist in the presence of allosteric drugs that modify agonist affinity and efficacy. Three mathematical methods are described and applied to analyze the theoretical data. These are 1) a null method, which requires no assumption regarding the nature of the stimulus-response relationship, 2) a method based on a logistic relationship between the stimulus and response (i.e., operational model), and 3) a special case of the former method, in which the Hill slope of the concentration-response curve equals one. Finally, methods based on the operational model are used to analyze experimental data from the literature. The results show that it is possible to estimate the affinity of an allosteric drug in functional assays regardless of whether it influences the affinity and intrinsic efficacy of the agonist. Under all conditions, it is possible to measure the product of the allosteric changes in efficacy and affinity (i.e., reciprocal of the dissociation constant). If the allosteric agent influences the maximal response of the agonist, it is possible to distinguish the allosteric change in affinity from the change in efficacy.

METHODS

Theory

Allosterism: An allosteric drug binds at a secondary allosteric site on the receptor, distinct from the site at which the agonist binds. The scheme showing the interaction of an allosteric drug (A) with an agonist (X) at a receptor (R) is:



in which, K_X denotes the dissociation constant of the agonist-receptor complex, K_A denotes the dissociation constant of the allosteric drug-receptor complex, and αK_A and αK_X denote the corresponding dissociation constants when the receptor is occupied by both ligands. Receptor theory posits that the response to an agonist is a function (f) of the stimulus, with the stimulus being equivalent to the product of receptor occupancy and intrinsic efficacy (Stephenson, 1956; Furchgott, 1966). If it is assumed that the RA complex is inactive, then the stimulus (S) of an agonist in the presence of an allosteric drug is given by (Ehlert, 1988a):

$$S = \varepsilon[XR] + \varepsilon'[XRA] \quad 1$$

in which ε and ε' denote the intrinsic efficacies of the XR and XRA complexes, respectively.

As described previously (Ehlert, 1988a), making the appropriate substitutions yields:

$$S = \frac{\varepsilon X R_T}{X + K_X + AX/\alpha K_A + \alpha K_X/K_A} + \frac{\varepsilon' X R_T}{X + \alpha K_X + \alpha X K_A/A + \alpha K_A K_X/A} \quad 2$$

in which R_T denotes the total amount of receptors. This equation simplifies to:

$$S = \frac{Xq\varepsilon R_T}{X + pK_X} \quad 3$$

in which

$$p = \frac{1 + A/K_A}{1 + A/\alpha K_A} \quad 4$$

$$q = \frac{1 + \beta A/\alpha K_A}{1 + A/\alpha K_A} \quad 5$$

$$\beta = \frac{\varepsilon'}{\varepsilon} \quad 6$$

An equivalent form of equation 3 has been described by Christopoulos (see equation 1.21.8 (Christopoulos, 2000)). Also, the activation state model of Hall (2000) for allosteric interactions is entirely consistent with equation 3 under the condition where little receptor is active in the absence of agonist and the RA complex is inactive. Equation 3 shows that, in the absence of the allosteric modulator (i.e., $A = 0$ and therefore $p = 1$ and $q = 1$), the stimulus function resembles a one-site model with a maximum proportional to εR_T and the concentration of agonist eliciting a half-maximal stimulus equivalent to K_X . The effect of the allosteric modulator is to cause a concentration-dependent modification in either the observed dissociation constant or the maximal stimulus or both by the coefficients p and q , respectively. If it were possible to measure the stimulus directly - such as in voltage clamp experiments on a ligand-gated ion channel with a simple one-site occupancy curve - one could use regression analysis to fit equations 4 and 5 to the estimates of the relative change in potency and maximal current, respectively, to obtain estimates of K_X , α and β . Similarly, in enzyme assays, where the activity of the enzyme is measured directly, one could use regression analysis to fit equations 4 and 5 to the estimates of the allosteric change in the maximum velocity (V_{max}) and Michaelis constant (K_m) to obtain the allosteric parameters K_X , α and β . However in most pharmacological assays of function, it is impossible to measure the stimulus directly. Rather, a consequent, downstream response is usually measured. In this situation, the response can be described by the following equation:

$$response = f\left(\frac{Xq\varepsilon R_T}{X + pK_X}\right) \quad 7$$

in which f denotes the unknown stimulus-response function. Below, three different approaches for estimating the influence of an allosteric modulator on the affinity and efficacy of the agonist-receptor complex are described. The first involves eliminating the stimulus-response function from the analysis through the use of a null method. The second involves the use of the operational model to describe the stimulus-response function, and the third involves a special

case of the operational model in which the Hill slope of the concentration-response curve equals one.

Null method: One approach to estimate allosteric effects in functional assays is to compare equivalent tissue responses in the presence and absence of the allosteric drug (see Ehlert (1988a)) so that the unknown relationship between the stimulus and response is eliminated. Using this approach, the relationship describing equivalent tissue responses in the absence and presence of an allosteric drug is given by:

$$f\left(\frac{\epsilon X R_T}{X + K_X}\right) = f\left(\frac{X' q \epsilon R_T}{X' + p K_X}\right) \quad 8$$

in which X and X' denote the equiactive concentrations of agonist in the absence and presence of the allosteric drug, respectively. This equation simplifies to:

$$X = \frac{q X' K_X}{X' (1 - q) + p K_X} \quad 9$$

Equation 9 can also be rearranged in the form:

$$X' = \frac{p K_X}{q(1 + K_X/X) - 1} \quad 10$$

It is useful to define the term relative activity of the agonist in the presence of the allosteric modulator (RA), which represents the ratio of the allosteric change in intrinsic efficacy (q) divided by the allosteric change in the dissociation constant of the agonist (p):

$$RA = \frac{q}{p} \quad 11$$

Making the appropriate substitutions for p (equation 4) and q (equation 5) yields:

$$RA = \frac{1 + \gamma A/K_A}{1 + A/K_A} \quad 12$$

in which:

$$\gamma = \frac{\beta}{\alpha} \quad 13$$

The method for using equations 9, 10, 11 and 12 for the analysis of allosteric effects in functional assays is described below under “Results.”

Operational model: Although the null method just described has the advantage of being applicable for any type of stimulus-response function (i.e., any shape of concentration response curve), it is widely observed that agonists usually exhibit logistic concentration-response curves. Indeed a curve fitting procedure based on the following logistic equation is the most common computational method that investigators use to estimate the maximal response (E_{max}) and concentration of agonist eliciting half-maximal response (EC_{50}):

$$response = \frac{X^n E_{max}}{X^n + EC_{50}^n} \quad 14$$

in which n denotes the Hill slope. Several investigators have shown that if the input to the stimulus-response function (f) is the stimulus (i.e., product of receptor occupancy and intrinsic efficacy) and the output obeys the logistic function just described, then the stimulus-response function must be the following (Furchgott, 1966; Mackay, 1981; Kenakin and Beek, 1982; Black and Leff, 1983):

$$response = \frac{S^m M_{sys}}{S^m + K_E^m} \quad 15$$

in which M_{sys} denotes the maximum response of the system, K_E denotes the sensitivity of the stimulus-response function and m denotes the transducer slope factor. This exponent is related to, but not identical to, the Hill slope of the agonist concentration-response curve. Substitution of equation 3 for S in equation 15 above followed by simplification yields:

$$response = \frac{X^m M_{sys}}{X^m + \frac{(X + K_{obs})^m}{\tau_{obs}^m}} \quad 16$$

in which

$$K_{obs} = pK_X \quad 17$$

$$\tau_{obs} = q\tau \quad 18$$

$$\tau = \frac{\epsilon R_T}{K_E} \quad 19$$

It is useful to define the term *relative activity* (RA) of the agonist in the presence of the allosteric drug as:

$$RA = \frac{\tau_{obs} K_{obs}'}{\tau_{obs}' K_{obs}} \quad 20$$

in which τ_{obs}' and K_{obs}' denote the τ_{obs} and K_{obs} values of the agonist in the absence of the allosteric drug. By making the appropriate substitutions for K_{obs} and τ_{obs} (equations 17 and 18, respectively), it can be shown that equation 20 simplifies to equation 12. Also, it can be shown by substitution of equation 4 for p in equation 17 that the observed dissociation constant of the agonist (K_{obs}) in the presence of the allosteric drug divided by that measured in its absence (K_{obs}') is equivalent to:

$$\frac{K_{obs}}{K_{obs}'} = \frac{(1 + A/K_A)}{(1 + A/\alpha K_A)} \quad 21$$

In situations where the exponent m in equation 16 equals one, the Hill slope is also equal to one ($n = 1$), and equation 16 reduces to:

$$response = \frac{XE_{max}}{X + EC_{50}} \quad 22$$

in which

$$E_{max} = \frac{q\tau M_{sys}}{q\tau + 1} \quad 23$$

$$EC_{50} = \frac{pK_x}{q\tau + 1} \quad 24$$

When the Hill slope is equal to one, it is possible to estimate the *relative activity* (RA) of the agonist in the presence of the allosteric drug as:

$$RA = \frac{E_{max} EC_{50}'}{E_{max}' EC_{50}} \quad 25$$

in which EC_{50}' and E_{max}' denote the EC_{50} and E_{max} values of the agonist in the absence of the allosteric drug and EC_{50} and E_{max} denote those measured in the presence of the allosteric drug. By making the appropriate substitutions for the various EC_{50} and E_{max} values (equations 23 and 24, respectively), it can be shown that equation 25, like equation 20, also simplifies to equation 12.

The use of equations 20, 21 and 25 in the analysis of allosteric effects in functional assays is described below under “Results.”

RESULTS

Simulation of Allosterism in Functional Assays

The influence of allosteric modulators on the agonist concentration-response curve has been simulated by Kenakin (Kenakin, 1997) and Christopolous (Christopoulos, 2000) for a variety of conditions. These simulations and the theory for allosterism (Ehlert, 1988a) show that an allosteric modulator causes a concentration-dependent change in the agonist concentration-response curve. The magnitude of this change approaches a limit with high concentrations of the modulator. Allosteric changes in affinity are manifest as a parallel shift in the agonist concentration-response curve along the abscissa, whereas a modulation in efficacy is usually manifest as a shift or both a shift and change in the maximal response, depending upon the receptor reserve. Below, four simulations are shown to provide examples for the analysis of allosteric interactions.

Allosteric modulator causing a decrease in both agonist affinity and efficacy: The behavior of allosterism in functional assays can be appreciated by using equation 16 to generate agonist concentration-response curves in the presence of an allosteric drug having differential effects on agonist affinity and intrinsic efficacy. Figure 1*a-c* shows the effect of an allosteric drug causing a maximal 90% reduction in intrinsic efficacy ($\beta = 0.1$) and observed affinity (10-fold increase in K_{obs} ; $\alpha = 10$) for a response exhibiting a Hill slope (n) of one ($m = n = 1$). When there is little receptor reserve, increasing concentrations of the allosteric inhibitor cause a shift to the right and a decrease in the maximal response of the agonist concentration-response curve (Figure 1*a*). However, with an intermediate receptor reserve (see Figure 1*b*) there is less of a decline in E_{max} and a greater shift to the right in the agonist concentration-response curve. With a large receptor reserve (Figure 1*c*), there is practically no decrease in E_{max} and a maximal 100-fold shift to the right in the agonist concentration-response curve. The EC_{50} and E_{max} values of the agonist in the

presence of different concentrations of the allosteric inhibitor were estimated by nonlinear regression analysis of the data according to equation 13, and these values are listed in Table 1 for the data shown in Figures 1a-c.

To investigate the influence of the Hill slope on the behavior of allosterism, the effects of an allosteric drug essentially identical to that described for Figure 1a-c were simulated, but with the response of the agonist exhibiting a Hill slope (n) greater than one. This change was accomplished by setting the transducer slope fraction in the operational model (m) equal to two. As shown in Figure 2a-c, behavior generally consistent with that observed in Figure 1a-c was observed. The effects of the allosteric inhibitor on the EC_{50} and E_{max} values of the agonist concentration-response curves shown in Figure 2 are listed in Table 2.

Allosteric modulator causing an increase in both agonist affinity and efficacy: The effects of an allosteric modulator causing both an increase in affinity and intrinsic efficacy of the agonist are shown in Figures 3a-c. In these simulations the maximal increases in affinity and efficacy were both ten-fold (i.e., $\alpha = 0.1$ and $\beta = 10$), and the response exhibited a Hill slope (n) of one ($m = n = 1$). When there is little receptor reserve, increasing concentrations of the allosteric enhancer cause a shift to the left and an increase in the maximal response of the agonist concentration-response curve (Figure 3a). However, with an intermediate receptor reserve (see Figure 3b) there is a very small increase in E_{max} and a greater increase in potency. With a large receptor reserve (Figure 3c), there is essentially no change in E_{max} and a maximal 100-fold shift to the left in the agonist concentration-response curve. The effects of the allosteric enhancers on the EC_{50} and E_{max} values for all of the curves show in Figure 3a-c are listed in Table 3.

Allosteric modulator having opposite effects on agonist affinity and efficacy: The effects of an allosteric modulator causing equal and opposite modulation of agonist affinity and intrinsic efficacy were simulated. Figure 4a - c shows the effects of an allosteric modulator causing a maximal ten-fold increase in agonist affinity ($\alpha = 0.1$) and a maximal 90% reduction in agonist

efficacy ($\beta = 0.1$) with the response exhibiting a Hill slope (n) of one ($m = n = 1$). When the receptor reserve is low (Figure 4a), the allosteric modulator causes a concentration-dependent decrease in both the E_{max} and EC_{50} values, so that the concentration response curve shifts to the left with a lowered maximum. Similar effects are observed when the receptor reserve is intermediate. However, when the receptor reserve is great, the allosteric inhibitor has little effect on the concentration-response curve because the reduction in efficacy is offset by an equivalent increase in affinity. The effect of the allosteric modulator on the EC_{50} and E_{max} values of the data simulated in Figure 4 are listed in Table 4.

Methods for the analysis of allosterism in functional assays

The methods for the analysis of allosterism presented here can be divided into two main categories, based on the application of the operational model and the null method described under “Methods.” These approaches are described below in Sections 1 and 2, respectively, where they are applied in the analysis of the simulated data in Figures 1 – 4. In Section 3, a set of experimental data from the literature is analyzed.

Section 1: Operational Model:

The application of the operational model to the analysis of allosterism in functional assays involves three steps: 1) estimation of the RA values of the agonist in the presence of different concentrations of the allosteric modulator, 2) estimation of the K_{obs}/K_{obs}' ratios in the presence of different concentrations of the allosteric modulator, and 3) nonlinear regression analysis of the foregoing RA values and K_{obs}/K_{obs}' ratios according to equations 12 and 21, respectively. This analysis ultimately yields estimates of K_A and γ (equation 12) as well as α (equation 21), and hence β , since $\beta = \gamma\alpha$. In the case where the Hill slopes of the agonist concentration-response curves do not differ significantly from one, it is possible to estimate the

RA values from the E_{max} and EC_{50} values of the concentration-response curves. Thus, in this instance, the concentration-response curves can be analyzed independently, using a nonlinear regression program (e.g., Prism, GraphPad Software, Inc., San Diego, CA) to estimate the EC_{50} and E_{max} values of each curve by fitting the standard equation for a sigmoidal dose-response curve having a Hill slope of one (equation 22) to the data. In situations where the Hill slopes differ from one, the RA values are estimated from the τ_{obs} and K_{obs} values. These latter values can only be estimated by global nonlinear regression analysis according to equation 16, which involves analyzing all of the curves measured at different amounts of allosteric modulator simultaneously, sharing estimates of M_{sys} and m among the curves. Similarly, estimation of the cooperativity factor α always involves global nonlinear regression analysis of all of the concentration response curves, regardless of the estimate of the Hill slope.

Estimation of K_A and γ when the Hill slope is equivalent to one: Since the agonist concentration-response curves shown in Figure 1a - c all exhibit Hill slopes of one, accurate estimates of the relative activity (RA) of the agonist can be estimated from the E_{max} and EC_{50} values using equation 25. These RA values are listed in Table 1 for the different concentrations of allosteric modulator. Figure 5a shows the Log RA values plotted against the Log of the concentration of allosteric modulator for the data from Figure 1a. In the presence of maximally effective concentrations of the allosteric modulator, the plot approaches an asymptote corresponding to the maximal combined change in observed affinity (α) and intrinsic efficacy (β) of the agonist. This combined effect on affinity and efficacy is denoted as γ and is equivalent to β/α (see equation 13). The Log form of equation 12 was fitted to the data by nonlinear regression analysis, which yielded estimates of 10^{-5} M and 0.01 for the K_A and γ , respectively. These estimates are essentially identical to those used in simulating the data in the first place, demonstrating that the nonlinear regression method provides accurate estimates of the allosteric parameters of the modulator. The same procedure was used to analyze the simulated data in Figure 1b and c, and identical results were obtained. This result was expected since the only difference among the

plots in Figure 1a - c is the receptor reserve (τ), and not the parameters of the allosteric modulator.

The functional data in Figure 3 for the allosteric modulator causing an increase in agonist affinity and efficacy can be analyzed in a manner analogous to that described above for the allosteric inhibitor in Figure 1 because both sets of data exhibit Hill slopes of one. Figure 5c shows a plot of the RA values (see Table 3) of the agonist plotted against the log of the allosteric modulator concentration for the data in Figure 3a - c. Regression analysis of the data according to equation 12 yielded estimates of 10^{-5} M and 100 for K_A and γ , respectively. These values are identical to those used in the simulation of the data.

The functional data in Figure 4a - c can also be analyzed in a manner similar to that described for Figure 1a - c. Since the Hill slopes of the curves are equal to one, the RA values can be calculated according to equation 25, and these values are listed in Table 4. Figure 5e shows that the plot of Log RA against Log A yield a horizontal line at $RA = 1$. Thus, it is impossible to estimate K_A from this plot, since any value of K_A will yield a best fit of equation 12 to the data as long as $\gamma = 1$. In this case where $\alpha/\beta = 1$, the K_A value can be estimated through the analysis of the K_{obs} values as described in the next section.

Resolution of γ into its α and β components when the Hill slope is equivalent to one: To discriminate between the modulatory effects of the allosteric agent on the observed dissociation constant and intrinsic efficacy of the agonist receptor complex, it is necessary to fit the operational model (equation 16) to all of the agonist concentration-response curves with varying allosteric modulator simultaneously. With regard to the data in Figure 1, regression analysis is done sharing the estimate of M_{sys} among all of the curves and estimating unique values of K_{obs} and τ_{obs} for each curve. Since all of the curves have Hill slopes of one, the exponent m can be removed from equation 16 or constrained at a constant value of one. Global nonlinear regression analysis of the data in Figure 1a yielded an estimate of 1.0 for M_{sys} , essentially the same as that used in the simulation of the data. The values of τ_{obs} and K_{obs} for the various concentrations of

allosteric modulator are listed in Table 1. The relative activity (RA) values of the agonist can also be estimated from the τ_{obs} and K_{obs} values for each concentration of allosteric modulator using equation 20, and these are also listed in Table 1. These RA values are essentially identical to those estimated from the E_{max} and EC_{50} values of the agonist (compare the last two columns in Table 1). Figure 5b shows a plot of the Log ratio (K_{obs}/K_{obs}') against the Log concentration of the allosteric modulator. It can be seen that this ratio reaches a plateau corresponding to α at high concentrations of allosteric modulator. Nonlinear regression analysis was used to fit the Log form of equation 21 to the data, which yielded estimates of 10^{-5} M and 10 for K_A and α , respectively. This estimate of K_A is identical to that estimated from the RA values shown in Figure 5a and that used in the simulations, and the estimate of α is equivalent to that used in the simulations. Knowing γ and α , it is possible to estimate β by rearrangement of equation 13 ($\gamma = \beta/\alpha$), which yields an estimate of 0.1 for β . This value is identical to that used in the simulations.

A similar analysis was done to estimate the τ_{obs} and K_{obs} values for the concentration-response curves shown in Figure 1b, and these parameters are also listed in Table 1. The corresponding RA values were estimated (see Table 1), and found to be identical to those estimated from the curves in Figure 1a. Consequently, plots identical to those shown in Figure 5a and b were derived for the curves in Figure 1b, and the same values for K_A , α , β and γ were estimated.

Under normal circumstances, where actual experimental data are analyzed, it would be difficult to obtain unique values of τ_{obs} and K_{obs} for each curve shown in Figure 1c because all of the E_{max} values of the curves are approximately the same. However, with the simulated data in Figure 1c, it is possible to obtain these estimates because the data have no error and there are actually small differences in the E_{max} values. Regardless, in the situation of little change in E_{max} , it is always possible to obtain accurate estimates of the ratio of the two parameters (i.e., τ_{obs}/K_{obs}), even though estimation of the individual values may be impossible. The nonlinear regression method for obtaining this ratio is described below in connection with Figure 6. As described in the next section, it is possible to estimate the RA values from these ratios, and these

estimates are listed in Table 1. The estimates of τ_{obs} and K_{obs} for the data in Figure 1c have been omitted from Table 1 because they would be difficult to estimate in experiments with data having moderate experimental error.

The approach described for the estimation of α from the data in Figure 1 was applied to the data in Figures 3 and 4, and the results are summarized in Tables 3 and 4. Figure 5d shows the ratio of K_{obs} values plotted against the log of the allosteric enhancer concentration for the data in Figures 3a and b. Regression analysis (equation 21) yielded estimates of 10^{-5} M and 0.1 for K_A and α , respectively. Knowing γ and α , it is possible to estimate a value of 10 for β using equation 13. Figure 5f shows a plot of the Log ratio (K_{obs}/K_{obs}') against Log A for the data in Figures 4a and b. Regression analysis according to equation 21 yielded estimates of 10^{-5} M and 0.1 for K_A and α , respectively. Knowing that the horizontal plot in Figure 5e with $RA = 1$ implies that $\gamma = 1$, it is possible to estimate that $\beta = 0.1$ by rearrangement of equation 13. It is impossible to estimate any allosteric parameters from the data in Figure 4c because the allosteric modulator has little or no effect on the concentration-response curve. This situation occurs because the allosteric effects on affinity and intrinsic efficacy are equal and opposite. When there is a large receptor reserve, the ten-fold reduction in intrinsic efficacy is manifest as a ten-fold shift to the right in the concentration-response curve, whereas the ten-fold increase in affinity causes the opposite effect, resulting in no net effect.

Estimation of allosteric parameters when the Hill slope differs from one and there is a modulation of E_{max} : To analyze the data shown in Figure 2 according to the operational model, it is inaccurate to estimate agonist RA from their EC_{50} and E_{max} values according to equation 25 because the Hill slopes of the concentration-response curve differ from 1. Consequently, equation 16 was fitted to all of the concentration response-curves simultaneously, sharing the estimate of M_{sys} and the exponent m among the curves and estimating unique values of τ_{obs} and K_{obs} for each curve. The global estimates of M_{sys} and m from regression analysis were 1.0 and 2.0 for M_{sys} and m , respectively. These values are identical to those used in the simulations. The

estimates of τ_{obs} and K_{obs} were used to calculate the agonist RA values (see equation 20). These RA estimates are listed in Table 2 and are essentially the same as those listed in Table 1 for the curves shown in Figure 1a and b. This result was expected because the only difference between the parameters for the data in Figure 1a - c and Figure 2a - c is the value of m , but not any of the other parameters, including the RA values. Consequently, analysis of the RA values for Figures 2a and b yields plots essentially identical to those shown in Figures 5a and b, and the K_A , α and β estimates for the allosteric drug were 10^{-5} M, 10 and 0.1, respectively.

Estimation of allosteric parameters when the Hill slope differs from one and there is no modulation of E_{max} : Since the receptor reserve is great for Figure 2c and all of the agonist concentration-response curves exhibit nearly the same E_{max} , numerous combinations of τ_{obs} and K_{obs} all yield the same least squares fit. Nevertheless, it is possible to estimate the ratio of τ_{obs}/K_{obs} for each curve shown in Figure 2c. A least squares fit can be obtained when the value of K_{obs} is equal to or greater than the larger of the two constants, K_X or αK_X . Thus, the best fit can be obtained by constraining K_{obs} as a constant at any arbitrary value equal to or greater than the true value of αK_X (10^{-4} M) and estimating unique values of τ_{obs} for each of the curves. A summary of this analysis is illustrated in Figure 6, which shows the best fitting parameter estimates for various values of K_{obs} between 10^{-8} M and 10^{-1} M as well as the residual sum of squares (RSS). The ordinate scale on the left corresponds to the various parameter estimates, whereas that on the right corresponds to RSS . The data in Figure 6 are from the concentration-response curve simulated in the presence of 10^{-4} M A; analogous plots can be made for the data simulated at the other concentrations of A. The estimate of RSS in the figure is based on all of the curves, not just the one simulated at $A = 10^{-4}$ M. As the constrained value of K_{obs} increases to 10^{-4} , RSS approaches a minimum plateau and remains at this best fitting level with a further increase in K_{obs} no matter how large. Thus, it can be seen that a least squares fit is obtained once the value of K_{obs} is equal to or greater than αK_X (10^{-4}). As the value of K_{obs} increases, the estimate of τ_{obs} increases in a proportional fashion so that the ratio of the two estimates (τ_{obs}/K_{obs})

is constant (Figure 6). Thus, the best fitting estimate of the ratio τ_{obs}/K_{obs} can be obtained by constraining K_{obs} to an arbitrarily high constant value and estimating the other parameters that minimize RSS . Using this approach, the ratio of τ_{obs}/K_{obs} was estimated for each of the curves shown in Figure 2c. Alternatively, it is possible to set τ_{obs} as a constant and estimate the value of K_{obs} that gives the least squares fit (analysis not shown).

Knowing the ratio of τ_{obs}/K_{obs} for each of the curves shown in Figure 2c, it is possible to estimate their respective RA values by dividing the ratio estimated in the presence of a given concentration of A by the corresponding ratio obtained for the control curve. In other words, if the τ_{obs}/K_{obs} ratio of one curve is divided by the corresponding ratio for the control curve (τ_{obs}'/K_{obs}') then the following ratio ($\tau_{obs}K_{obs}'/\tau_{obs}'K_{obs}$) is obtained, which is equivalent to the RA value (see equation 20). The RA values for the data in Figure 2c were estimated in this manner and are listed in Table 2. These values are identical to those estimated for the data in Figures 1a - c and Figures 2a and b; consequently, regression analysis of these data according to equation 20 yields a plot identical to that shown in Figure 5a with K_A and γ estimates of 10^{-5} M and 0.01, respectively. Since it was impossible to estimate unique K_{obs} values for each of the curves shown in Figure 2c, it was impossible to separate γ into its α and β components. As described above, it is impossible to make this distinction when the allosteric inhibitor has no influence on the E_{max} of the concentration-response curve.

It is informative to estimate the RA values of the data shown in Figure 2 from the E_{max} and EC_{50} values according to equation 25. As described above, this equation is only appropriate for conditions when the Hill slopes of the agonist concentration-response curve are equal to one. When these estimate were made, and the data analyzed according to the plots shown in Figure 5a and b, estimates of 5.5×10^{-6} M and 0.00073 (Figure 2a) and 9.21×10^{-6} M and 0.0037 (Figure 2b) were made for K_A and γ , respectively. Thus, there is substantial error in these parameters estimates, which should equal 10^{-5} M and 0.01. However, when this method was used to analyze the data in Figure 2c, values of 10^{-5} M and 0.0090 were estimated for K_A and γ , respectively. Note that the latter value of K_A is correct, whereas the estimate of γ is only off by 10%. Thus,

when the allosteric inhibitor has no influence on E_{max} it is possible to estimate the RA values according to equation 25, even if the Hill slopes differ from 1. This conclusion seems reasonable because the two different methods for calculating the RA value (equations 20 and 25) yield similar estimates for the data in Figure 2c but not for those of Figures 2a and b (Compare the last two columns of Table 2). Note that when the allosteric inhibitor has no effect on the E_{max} , the estimation of RA from equation 25 can be simplified to:

$$RA = \frac{EC_{50}'}{EC_{50}} \quad 26$$

Figure 7 shows the ratio of EC_{50} values of the agonist in the presence of the allosteric drug divided by that measured in its absence plotted against the Log of the allosteric drug concentration for the data from Figure 2c. Nonlinear regression analysis of the data according to the Log form of equation 20 yielded estimates of 10^{-5} M and 0.009 for K_A and γ , respectively, as described above.

In summary, it can be concluded that whenever an allosteric modulator is without effect on E_{max} , only K_A and γ can be estimated. Under these conditions, one can estimate the RA values from Equation 25 or 26 even if the Hill slope differs from one. Equation 12 can be fitted to the data by nonlinear regression analysis to obtain estimates of K_A and γ . It is unnecessary to perform the complicated regression analysis summarized in Figure 6 to estimate the RA values in this situation. Nevertheless, this analysis has been presented here to illustrate the relationship among the various parameter estimates in this situation.

Section 2: Null Method

An advantage of the null method for the analysis of allosteric interactions is that it can be applied to agonist concentration-response curves that deviate from logistic behavior. Nevertheless, the method will be used here to analyze the logistic curves shown in Figures 1 and 3. The null method involves three steps: 1) estimation of equiactive concentrations of agonist in

the absence (X) and presence (X') of the various concentrations of the allosteric modulator, 2) global nonlinear regression analysis of the Log equiactive agonist concentrations to obtain estimates of the ratio q/p (RA values; see equation 11) of the agonist in the presence of different concentrations of the allosteric modulator, and 3) nonlinear regression analysis of the foregoing RA values according to equation 12. This analysis yields estimates of K_A and γ .

Allosteric modulator causes a reduction in E_{max} : Figure 8 shows the application of this method for the data in Figure 1a. Since the allosteric modulator causes a reduction in the E_{max} of the agonist, the agonist concentrations (X) are interpolated from the control concentration-response curve that yield responses equivalent to those elicited by the agonist concentrations (X') used in the presence of the allosteric modulator (see Figure 8a for the data simulated at $A = 10^{-3}$ M). These pairs of equiactive agonist concentrations are then plotted on a Log scale as shown in Figure 8b. Each curve in Figure 8b corresponds to a different allosteric modulator concentration. These curves were analyzed simultaneously by global nonlinear regression analysis of the data according to the Log form of equation 9, with the estimate of K_X shared among all the curves and unique values of p and q estimated for each curve. However, it is possible to estimate numerous combinations of K_X , p and q that yield the same least squares fit for each curve. Using an approach analogous to that described above in connection with Figure 6, it is possible to estimate the ratio q/p (RA ; see equation 11), by constraining K_X to a constant and determining the values of the other parameters that minimize RSS . Figure 8c shows the results of regression analysis for the data simulated at $A = 10^{-3}$ M. Over the range of K_X values shown (10^{-9} - 10^{-1}), RSS was insignificant and depended only on the criteria used for convergence of the nonlinear regression algorithm and not on K_X . Analogous behavior was observed for the data simulated at the other concentrations of A . Using this approach, various values of RA can be estimated at various the concentrations of the allosteric modulator (A). The resulting Log RA values are plotted against Log A and analyzed by nonlinear regression analysis according to equation 11. The results yielded a plot identical to that shown in Figure 5a, and values of 10^{-5} M and 0.01 were estimated

for K_A and γ , respectively. These values are identical to those used in the simulation of the data in Figure 1a. The data in Figure 1b were analyzed in a similar fashion and the same estimates of γ and K_A were obtained (i.e., 0.01 and 10^{-5} M, respectively).

It is also possible to use the same strategy for the simulated data in Figure 1c; however, since the data exhibit little or no change in E_{max} with allosteric modulation, it is necessary to constrain both K_X and p as constants and analyze all of the data simultaneously by global nonlinear regression analysis (equation 9) to obtain q values for each of the curves. By dividing the estimates of q value by the constant value of p , it is possible to obtain the RA estimates for each curve, and hence, the values of γ and K_A by regression analysis according to equation 12. When this was done, a plot identical to that shown in Figure 5a was obtained as well as the same estimates of γ and K_A (0.01 and 10^{-5} M, respectively). Regardless, this complicated analysis is probably unnecessary because the RA values can be estimated accurately from EC_{50} values according to equation 26 when there is little change in E_{max} with the allosteric modulator. Presumably, this situation would apply to non-logistic agonist concentration-response curves.

Allosteric modulator causes an increase in E_{max} : In situations where the allosteric modulator causes an increase in the E_{max} of the agonist, it is possible to analyze the data according to null equation 10. However, in this instance, where the concentration-response curve in the presence of the allosteric modulator has a greater E_{max} than that measured in its absence, the X' values are interpolated from the curve measured in the presence of the allosteric inhibitor that yield responses equivalent to those generated by the concentrations (X) of the control concentration-response curve. Using this approach and an overall strategy analogous to that just described in the preceding paragraph, it is possible to estimate the γ and K_A values for the allosteric enhancer shown in Figures 3a – c. However, an important difference is the range of values over which the parameter K_X can be constrained as a constant for global nonlinear regression analysis. This range was found to be $K_X \leq 10^{-5}$ for the data in Figure 3. When this analysis was done, plots

identical to that shown in Figure 5c were obtained, and values of 100 and 10^{-5} M were estimated for γ and K_A , respectively, which are equivalent to those used in simulating the data.

Using the null approach, it is also possible to estimate the γ and K_A values of the other allosteric modulators simulated above, with the exception of the data in Figure 4. In this case, the plot of RA against $\text{Log } A$ yields a horizontal line at $RA = 1$ as shown in Figure 5e. As described above, it is impossible to estimate K_A from this figure, only γ . In summary, if the allosteric modulator causes a decrease in E_{max} , the approach describe in connection with Figure 10 is used, whereas if an increase in E_{max} is observed, the approach described in the preceding paragraph is used.

Section 3: Experimental data

The methods based on the operational model were applied to experimental data to determine the impact of experimental error on the estimates of allosteric parameters. Figure 9a shows the results of a prior study in which the influence of gallamine on muscarinic receptor mediated inhibition of adenylyl cyclase activity was measured in homogenates of the rat myocardium (Ehlert, 1988b). This preparation is known to contain a relatively homogeneous population of M_2 muscarinic receptors (Hammer et al., 1986). Gallamine is a neuromuscular blocking agent long known to cause sinus tachycardia (Walton, 1950) through a mechanism involving an inhibition of postjunctional muscarinic receptors (Riker and Wescoe, 1951). The mechanism was later shown to be allosteric in functional studies on isolated beating hearts (Clark and Mitchelson, 1976) and in muscarinic receptor binding assays (Stockton et al., 1983).

As shown in Figure 9a, gallamine caused a concentration-dependent shift to the right in the agonist concentration-response curve with little change in E_{max} . Regression analysis of each curve according to logistic equation 14 yielded the estimates of EC_{50} , E_{max} and n (Hill slope), and these values are listed in Table 5. The results show that the agonist concentration-response curves exhibit low Hill slopes (approximately 0.7 – 1.0) and that there is little change in E_{max} . In

this situation, it is only possible to estimate K_A and γ ; it is impossible to resolve γ into its α and β components from these data alone (see analysis of the data in Figures 1c and 3c). Accordingly, the RA value of the agonist can be estimated easily by calculating the ratio of EC_{50} values measured in the presence of gallamine divided by that measured in its absence as described above in equation 26. Nevertheless, the RA values were estimated using the operational model so that the influence of experimental error on these estimates might be appreciated. Normally, this method would only be required in situations where the allosteric modulator influences the E_{max} .

The data were analyzed by global nonlinear regression analysis according to equation 16 using the procedure described above in connection with Figure 6 for the estimation of RA values. Regression analysis was done sharing the estimates of M_{sys} and m among the curves and constraining K_{obs} as a constant so that the ratio τ_{obs}/K_{obs} could be estimated. A summary of the analysis of the data at 10^{-4} M gallamine is shown in Figure 9b where the logarithm of the parameter estimates are plotted against K_{obs} , which was constrained to various fixed values during regression analysis. A least squares fit was obtained over the range $K_{obs} > 10^{-3}$ as shown by the minimum value for Log RSS. Over this range the estimates of M_{sys} , m and the ratio τ_{obs}/K_{obs} were constant. This process was repeated for each curve in Figure 9a, and a least squares fit was always obtained over the domain $K_{obs} > 10^{-3}$. The estimates \pm S.E. of M_{sys} and m were 55 ± 1.4 % inhibition and 0.68 ± 0.037 , respectively. The RA values were calculated from the τ_{obs}/K_{obs} ratios estimated with K_{obs} constrained to an arbitrarily high value (i.e., 10^{-2}), and these estimates are also listed in Table 5 and plotted in Figure 9b. Regression analysis of the data according to equation 12 yielded estimates of K_A and γ of $0.62 \mu\text{M}$ and 0.019 , respectively (mean \pm S.E.M.: pK_A , 6.21 ± 0.15 ; $\text{Log } \gamma = -1.72 \pm 0.16$).

For heuristic purposes, the RA values were also estimated using equation 25. Generally, the use of equation 25 is restricted to data with Hill slopes of one, but as described above, it is applicable in situations where there is little change in E_{max} . These estimates were made for each experiment and the mean values of four experiments \pm S.E.M. are listed in Table 5. The

corresponding Log RA values are also plotted against the Log of the gallamine concentration in Figure 9c. Regression analysis of the data according to equation 12 yielded estimates of K_A and γ of 0.56 μM and 0.025, respectively (mean \pm S.E.M.: pK_A , 6.25 ± 0.21 ; Log $\gamma = -1.60 \pm 0.21$).

DISCUSSION

The study of allosterism in functional assays provides potential information about the allosteric modulation of the intrinsic efficacy of the agonist-receptor complex. This information is important because the therapeutic effects of allosteric modulators depend on their modulation of both the affinity and intrinsic efficacy of the endogenous ligand. The theoretical basis for the present analysis was described in a prior report (Ehlert, 1988a), where it was shown that simple graphical techniques can be used to estimate the affinity of the allosteric modulator and its combined effects on the affinity and intrinsic efficacy (γ) of the agonist-receptor complex when the receptor reserve is great. Given the widespread availability of software for nonlinear regression analysis, the time seemed appropriate to reinvestigate this method and to apply it to all conditions. To this end, the concept of relative activity of the agonist (RA) is developed here and shown to be a robust measure of allosteric effects.

The present report shows that it is always possible to estimate the influence of the allosteric modulator on the RA value of the agonist. Regression analysis of the RA values according to the logarithmic form of equation 12:

$$\text{Log}(RA) = \text{Log}\left(\frac{1 + \gamma A/K_A}{1 + A/K_A}\right) \quad 27$$

provides estimates of the dissociation constant (K_A) of the allosteric modulator as well as the product (γ) of its modulatory effects on the intrinsic efficacy (β) and affinity ($1/\alpha$) of the agonist-receptor complex. In situations where the Hill slopes of the agonist concentration-response curves are equal to one, the RA values can be estimated easily from the EC_{50} and E_{max} values (see equation 21). If the allosteric modulator has no influence on the E_{max} of the agonist, it is impossible to determine the individual components of γ (α and β) unless an independent estimate of α is made, perhaps through ligand binding analysis (see Lazareno et al. (1995)). If the allosteric modulator does influence the E_{max} of the agonist, then it is possible to estimate the individual components α and β as described above under Results. The method involves global

nonlinear regression analysis with the operational model (equation 15) to obtain individual estimates of τ_{obs} and K_{obs} .

For heuristic purposes, this analysis has emphasized the utility of the RA estimate in understanding allosteric interactions. Consequently, the Log RA value has been treated as the dependent variable in nonlinear regression analysis. However, this strategy might not be the best statistical approach when the RA value is estimated from the EC_{50} and E_{max} values in situations where the Hill slope is equivalent to one. For example, if there is error in the estimates of the E_{max} and EC_{50} values of the control concentration-response curve, then this error will introduce a systematic error in the RA estimates for all the concentration-response curves measured in the presence of the allosteric modulator. A better strategy might be to calculate Log ratio of the E_{max}/EC_{50} values measured in the absence and presence of the various concentrations of the allosteric modulator and use the following equation to analyze the data by nonlinear regression analysis:

$$\text{Log}\left(\frac{E_{max}}{EC_{50}}\right) = P + \text{Log}\left(\frac{1 + \gamma A/K_A}{1 + A/K_A}\right) \quad 28$$

Regression analysis should yield estimate of γ , K_A and P , the Log ratio of E_{max}'/EC_{50}' for the control agonist concentration-response curve. The latter equation can be derived from equations 25 and 26, and it only applies to situations where the Hill slope of the concentrations response curves are equivalent to one. Also, when the Hill slope is equivalent to one and the allosteric modulator has no influence on E_{max} , the above equation reduces to that previously described (Ehlert, 1988b):

$$\text{Log}(EC_{50}) = \text{Log}(EC_{50}') + \text{Log}\left(\frac{1 + A/K_A}{1 + \gamma A/K_A}\right) \quad 29$$

Regression analysis would yield estimates of γ , K_A and the Log control EC_{50} value. A similar statistical argument might seem appropriate when the RA values are estimated from K_{obs} and τ_{obs} (i.e., error in the estimates of K_X and τ will introduce a systematic error in the estimate of RA); however, this concern is unnecessary because the values of K_X and τ (K_{obs}' and τ_{obs}') are estimated by global nonlinear regression analysis (equation 10) of all of the agonist

concentration-response curves simultaneously. Thus, all of the data is considered in the estimation of K_X and τ and not just the control data.

It should be apparent from the foregoing that it is possible to estimate the dissociation constant of the agonist (K_X) through the analysis of an allosteric modulator that influences the intrinsic efficacy of the agonist to such an extent that a change in E_{max} is observed.

The present report also describes a null method, whereby the values of K_A and γ were determined by nonlinear regression analysis of pairs of equiactive agonist concentrations in the absence and presence of various concentrations of the allosteric modulator. This type of approach should be applicable in situations where the response of the agonist deviates from logistic behavior.

The estimates of the K_A (0.56 – 0.62 μ M) and γ (0.019 – 0.025) values for gallamine antagonism of the action of oxotremorine-M at M_2 muscarinic receptors made in this report by regression analysis of the Log RA values are in good agreement with those (0.52 μ M and 0.020) made in a prior analysis of the same data utilizing regression analysis of the Log EC_{50} values according to equation 29 above (Ehlert, 1988b). This agreement shows the feasibility of estimating RA values from experimental data. The estimate of the K_A of gallamine reported here is also in good agreement with that (0.93 μ M) estimated by antagonism of the negative inotropic effect of acetylcholine in the isolated, electrically driven, guinea pig atrium (Christopoulos, 2000) and by competitive inhibition of the binding of [3 H]N-methylscopolamine to myocardial muscarinic receptors (Stockton et al., 1983; Ehlert, 1988b) (0.77 and 1.1 μ M, respectively).

In a prior report on the antagonism of the action of the highly efficacious agonist oxotremorine-M and the partial agonist BM-5 at cardiac M_2 muscarinic receptors by gallamine, the estimates of γ were calculated to be 0.020 and 0.011, respectively (Ehlert, 1988b). In both cases, gallamine had little or no effect on the E_{max} values of the agonists. Since BM-5 behaved as a partial agonist, any gallamine-induced change in the intrinsic efficacy of BM-5 should have been manifest as an alteration in E_{max} . The lack of this change indicates that $\beta = 1$ and $\alpha = 0.011$, approximately, for the allosteric interaction between gallamine and BM-5 (i.e., $\gamma = \alpha/\beta = 0.011$).

Additional proof for this hypothesis could be obtained if a similar estimate of the α value for the interaction between gallamine and BM-5 was obtained in ligand binding studies using the technique described by Lazareno and Birdsall (Lazareno and Birdsall, 1995).

The presumed lack of effect of gallamine on the intrinsic efficacy of BM-5 has important implications with regard to the action of gallamine and the number of ground and active states of the M₂ muscarinic receptor. In a simple two-state model, where there is only one active and one inactive state of the receptor, there should be a correlation between allosteric effects and the intrinsic efficacy of the primary ligand (Ehlert, 2000). However, gallamine has been shown to inhibit the binding of both agonists and antagonists to M₂ muscarinic receptors. Moreover, if gallamine reduces the affinity of BM-5 without influencing its intrinsic efficacy, this result implies the existence of another pair of ground and active states of the M₂ receptor that are selected by gallamine and whose affinities for BM-5 are both lower by the same amount so that the selectivity of BM-5 for the two states is the same, and hence, its efficacy unaltered (i.e., the ratio of microscopic affinity constants of BM-5 for the ground and active states are the same). Alternatively, a more complicated hypothesis involving a group of active and inactive states might explain the data.

Part of the analysis described herein is analogous to a method previously described for analyzing a series of concentration-response curves to different agonists with varying affinity and intrinsic efficacy. In that prior analysis, the concept of intrinsic relative activity (*IRA*) was developed (Ehlert et al., 1999; Ehlert and Griffin, 2001). This term denotes the product of the affinity and intrinsic activity of the agonist expressed relative to that of a standard agonist. This estimate is analogous to the *RA* value described here, which is a measure of the product of affinity and intrinsic efficacy of the agonist in the presence of the allosteric modulator relative to that measured in its absence.

Accurate measurements of the components of allosterism are important and likely to be more significant as the number of allosteric drugs used in therapeutics and research increases.

REFERENCES

- Black JW and Leff P (1983) Operational models of pharmacological agonism. *Proc. Roy. Soc. Lond. B* **220**:141-162.
- Burgen AS (1981) Conformational changes and drug action. *Fed. Proc.* **40**:2723-2728.
- Christopoulos A (2000) Quantification of allosteric interactions at G protein-coupled receptors using radioligand binding assays, in *Current Protocols in Pharmacology* (Enna SJ ed), Wiley & Sons, New York.
- Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. *Nat Rev Drug Discov* **1**:198-210.
- Clark AL and Mitchelson F (1976) The inhibitory effect of gallamine on muscarinic receptors. *Brit. J. Pharmacol.* **58**:323-331.
- Ehlert FJ (1986) 'Inverse agonists', cooperativity and drug action at benzodiazepine receptors. *Trends Pharmacol. Sci.* **7**:28-32.
- Ehlert FJ (1988a) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. *Mol. Pharmacol.* **33**:187-194.
- Ehlert FJ (1988b) Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium. *J. Pharmacol. Exp. Ther.* **247**:596-602.
- Ehlert FJ (2000) Ternary Complex Model, in *Biomedical Applications of Computer Modeling* (Christopoulos A ed) pp 21-85, CRC Press, Boca Raton.
- Ehlert FJ and Griffin MT (2001) Estimation of agonist activity and relative efficacy at G protein-coupled receptors: Mutational analysis and characterization of receptor subtypes. *Analytical Pharmacology* **2**:34-48.
- Ehlert FJ, Griffin MT, Sawyer GW and Bailon R (1999) A simple method for estimation of agonist activity at receptor subtypes: comparison of native and cloned M₃ muscarinic

- receptors in guinea pig ileum and transfected cells. *J. Pharmacol. Exp. Ther.* **289**:981-992.
- Furchgott RF (1966) The use of β -haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. *Adv. Drug Res.* **3**:21-55.
- Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. *Mol. Pharmacol.* **58**:1412-1423.
- Hammer R, Giraldo E, Schiavi GB, Monferini E and Ladinsky H (1986) Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. *Life Sci.* **38**:1653-1662.
- Kenakin TP (1997) *Pharmacologic analysis of Drug-receptor interaction*. Lippincott-Raven Publishers, Philadelphia.
- Kenakin TP and Beek D (1982) In vitro studies on the cardiac activity of prenalterol with reference to use in congestive heart failure. *J. Pharmacol. Exp. Ther.* **220**:77-85.
- Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. *Mol. Pharmacol.* **48**:362-378.
- Mackay D (1981) An analysis of functional antagonism and synergism. *Brit. J. Pharmacol.* **73**:127-134.
- Riker WF, Jr. and Wescoe WC (1951) The pharmacology of Flaxedil, with observations on certain analogs. *Ann N Y Acad Sci* **54**:373-394.
- Stephenson RP (1956) A modification of receptor theory. *Brit. J. Pharmacol.* **11**:379-393.
- Stockton JM, Birdsall NJ, Burgen AS and Hulme EC (1983) Modification of the binding properties of muscarinic receptors by gallamine. *Mol. Pharmacol.* **23**:551-557.
- Walton FA (1950) Flaxedil, a new curarizing agent. *Can Med Assoc J* **63**:123-129.

FOOTNOTES

^a This work was supported by National Institutes of Health Grant 69829

Send reprint requests to:

Frederick J. Ehlert, Ph.D.
Department of Pharmacology
College of Medicine
University of California, Irvine
Irvine, California 92697-4625

Legends to Figures

Figure 1: Simulation of the effects of an allosteric modulator inhibiting both agonist affinity and intrinsic efficacy on the concentration-response curve to an agonist having a Hill slope (n) of one (i.e., $m = n = 1$). In these examples, the allosteric modulator causes both a maximal ten-fold reduction in the affinity ($\alpha = 10$) and intrinsic efficacy ($\beta = 0.1$) of the agonist-receptor complex. Small ($\tau = 1$) (a), intermediate ($\tau = 10$) (b) and large ($\tau = 100$) (c) receptor reserves were simulated. The dissociation constant of the allosteric inhibitor (K_A) was 10^{-5} M and $M_{sys} = 1$. The concentrations of allosteric modulator are indicated in panel a for the entire figure.

Figure 2: Simulation of the effects of an allosteric inhibitor on the concentration-response curve to an agonist having a transducer slope factor in the operational model of two ($m = 2$). In this example, the allosteric modulator causes maximal ten-fold reductions in both affinity and intrinsic efficacy ($\alpha = 10$; $\beta = 0.1$) of the agonist-receptor complex. Small ($\tau = 1$) (a), intermediate ($\tau = 10$) (b) and large ($\tau = 100$) (c) receptor reserves were simulated. The dissociation constant of the allosteric inhibitor (K_A) was 10^{-5} M and $M_{sys} = 1$. The concentrations of allosteric modulator are indicated in panel a for the entire figure.

Figure 3: Simulation of the effects of an allosteric modulator enhancing both agonist affinity and intrinsic efficacy on the concentration-response curve to an agonist having a Hill slope (n) of one ($m = n = 1$). In these examples, the allosteric modulator causes both a maximal ten-fold increase in only the affinity ($\alpha = 0.1$) and intrinsic efficacy ($\beta = 10$) of the agonist-receptor complex. Small ($\tau = 1$) (a), intermediate ($\tau = 10$) (b) and large ($\tau = 100$) (c) receptor reserves were simulated. The dissociation constant of the allosteric inhibitor (K_A) was 10^{-5} M and $M_{sys} = 1$. The concentrations of allosteric modulator are indicated in panel a for the entire figure.

Figure 4: Simulation of the effects of an allosteric modulator on the concentration-response curve to an agonist having a Hill slope (n) of one ($m = n = 1$). In this example, the

allosteric modulator causes both a maximal ten-fold increase in affinity and a 10-fold decrease in intrinsic efficacy ($\alpha = 0.1$; $\beta = 0.1$) of the agonist-receptor complex. Small ($\tau = 1$) (a), intermediate ($\tau = 10$) (b) and large ($\tau = 100$) (c) receptor reserves were simulated. The dissociation constant of the allosteric inhibitor (K_A) was 10^{-5} M and $M_{sys} = 1$. The concentrations of allosteric modulator are indicated in panel a for the entire figure.

Figure 5: Effect of allosteric modulators on the RA (a, c and e) and K_{obs} (b, d and f) values of the agonist. The plots in a and b represent an analysis of the data shown in Figure 1a – c and 2a – c, and the estimates of RA and K_{obs} are from Tables 1 and 2. The plots in c and d represent an analysis of the data shown in Figure 3a – c, and the estimates of RA and K_{obs} are from Table 3. The plots in e and f represent an analysis of the data shown in Figure 4a – c, and the estimates of RA and K_{obs} are from Table 4. The dashed lines in a and c denote the maximal effect of the allosteric modulator on the RA value (γ). The dashed lines in b, d and f denote the maximal shift (α) of the allosteric modulator on the observed affinity of the agonist.

Figure 6: Summary of global nonlinear regression analysis of the data in Figure 2c at $A = 10^{-4}$ M according to equation 16. All of the curves in Figure 2c were fitted simultaneously sharing the estimate of m and M_{sys} among the curves and constraining the value of K_{obs} as a constant at various values between 10^{-5} and 10^{-1} . Regression analysis was used to estimate the values of the various parameters in equation 16 that yielded the least squares fit to the data. The plot shows how the estimate of τ_{obs} for the data simulated at $A = 10^{-4}$ M is proportional to K_{obs} such that their ratio (τ_{obs}/K_{obs}) remains constant at approximately 10^6 .

Figure 7: The influence of an allosteric inhibitor on the EC_{50} value of an agonist when the receptor reserve is great ($\tau = 100$) and the transducer slope factor in the operational model is equal to two ($m = 2$). The ratio of the control EC_{50} value divided by that measured in the presence of the allosteric modulator is plotted on a Log scale against the concentration of the allosteric modulator. The allosteric modulator causes a ten-fold reduction in the

affinity ($\alpha = 10$) and intrinsic efficacy ($\beta = 0.1$) of the agonist receptor complex. The plot represents an analysis of the data shown in Figure 2c. The EC_{50} values are from Table 2.

Figure 8: Estimation of the modulatory effects of an allosteric inhibitor using a null method.

The data are from Figure 1a. *a*: Pairs of equiactive agonist concentrations in the absence and presence of the allosteric modulator are estimated. This plot is for the data simulated for $A = 10^{-3}$ M; a similar analysis was done for the other concentrations of allosteric modulator. *b*: The logarithms of the equiactive agonist concentrations are analyzed by nonlinear regression analysis using equation 9. The curves are analyzed simultaneously sharing the estimates of K_X among the curves and estimating a unique value of p and q for each curve. *c*: Summary of nonlinear regression analysis for the data simulated at $A = 10^{-3}$ M. The value of K_X was constrained as a constant over the range of values shown on the abscissa and the values of the other parameters that yielded the least squares fit to the simulated data were estimated by regression analysis as shown by the indicated curves. It can be seen that the estimates of p and q are proportional to one another such that their ratio (q/p or RA) remains constant over the range of K_X values shown.

Figure 9: Analysis of the antagonism of oxotremorine-M-mediated inhibition of adenylyl

cyclase activity by gallamine in homogenates of the rat myocardium. *a*: Adenylyl cyclase activity was measured in the presence of various concentration of both oxotremorine-M and gallamine. The data are from Ehlert (1988b). Mean values \pm S.E.M. from four experiments are shown. *b*: Summary of global nonlinear regression analysis of the concentration-response curves shown in panel *a* at gallamine = 10^{-4} M according to equation 16. All of the curves were fitted simultaneously sharing the estimate of m and M_{sys} among the curves and constraining the value of K_{obs} as a constant at various values between 10^{-6} and 10^0 . Regression analysis was used to estimate the values of the various parameters in equation 16 that yielded the best least squares fit to the data. The plot shows how the estimate of τ_{obs} for the data simulated at gallamine = 10^{-4} M is proportional to K_{obs} such that their ratio (τ_{obs}/K_{obs}) remains constant at approximately 3.7×10^4 . *c*: Effect of

gallamine on the RA values of oxotremorine-M. The plots represent an analysis of the data shown in panel *a*, and the estimates of RA were calculated from the K_{obs} and τ_{obs} values or the E_{max} and EC_{50} values listed in Table 5.

Table 1: Estimates of EC_{50} , E_{max} , Hill slope, K_{obs} and τ_{obs} for the simulated data in Figures 1a – c. In this example the allosteric modulator causes a ten-fold reduction in both the affinity ($\alpha = 10$) and intrinsic efficacy ($\beta = 0.1$) of the agonist-receptor complex.

<i>Allosteric Modulator (M)</i>	<i>EC₅₀ (μM)</i>	<i>E_{max} (%)</i>	<i>Hill Slope</i>	<i>K_{obs} (μM)</i>	<i>τ_{obs}</i>	$\frac{E_{max} EC_{50}'}{E_{max} EC_{50}}$ _a (RA)	$\frac{\tau_{obs} K_{obs}'}{\tau_{obs} K_{obs}}$ _a (RA)
<i>τ = 1</i>							
0	5.00	50	1.0	10.0	1.00	1.00	1.00
10 ⁻⁵	9.46	47.9	1.0	18.2	0.918	0.506	0.505
10 ⁻⁴	35.5	35.5	1.0	55.0	0.550	0.100	0.100
10 ⁻³	78.2	15.4	1.0	91.8	0.182	0.0197	0.0198
10 ⁻²	89.1	9.8	1.0	99.1	0.109	0.0110	0.0110
<i>τ = 10</i>							
0	0.908	90.9	1.0	10.0	10.0	1.00	1.00
10 ⁻⁵	1.79	90.2	1.0	18.2	9.18	0.504	0.505
10 ⁻⁴	8.47	84.6	1.0	55.0	5.50	0.100	0.100
10 ⁻³	32.5	64.5	1.0	91.8	1.82	0.0197	0.0198
10 ⁻²	47.3	52.1	1.0	99.1	1.09	0.0110	0.0110
<i>τ = 100</i>							
0	0.0991	99.0	1.0	-	-	1.00	1.00
10 ⁻⁵	0.196	98.9	1.0	-	-	0.504	0.505
10 ⁻⁴	0.984	98.2	1.0	-	-	0.100	0.100
10 ⁻³	4.79	94.8	1.0	-	-	0.0198	0.0198
10 ⁻²	8.32	91.6	1.0	-	-	0.0110	0.0110

(Table 1 continued)

^a EC_{50}' , E_{max}' , K_{obs}' and τ_{obs}' denote the corresponding parameter values of EC_{50} , E_{max} , K_{obs} and τ_{obs} in the absence of allosteric modulator.

Table 2: Estimates of EC_{50} , E_{max} , Hill slope, K_{obs} and τ_{obs} for the simulated data in Figures 2a – c. In this example the allosteric modulator causes a ten-fold reduction in both the affinity ($\alpha = 10$) and intrinsic efficacy ($\beta = 0.1$) of the agonist-receptor complex.

<i>Allosteric Modulator (M)</i>	EC_{50} (μM)	E_{max} (%)	Hill Slope	K_{obs} (μM)	τ_{obs}	$\frac{E_{max} EC_{50}'}{E_{max} EC_{50}}$ ^a	$\frac{\tau_{obs} K_{obs}'}{\tau_{obs} K_{obs}}$ ^a (RA)
$\tau = 1$							
0	14.1	49.6	1.30	10.0	1.00	1.00	1.00
10^{-5}	27.4	45.3	1.29	18.2	0.918	0.472	0.505
10^{-4}	108	22.9	1.28	55.0	0.550	0.0606	0.100
10^{-3}	216	3.14	1.25	91.8	0.182	0.0041	0.0198
10^{-2}	237	1.15	1.25	99.1	0.109	0.0014	0.0110
$\tau = 10$							
0	1.11	98.7	1.80	10.0	10.0	1.00	1.00
10^{-5}	2.22	98.5	1.80	18.2	9.18	0.500	0.505
10^{-4}	11.9	96.3	1.68	55.0	5.50	0.0908	0.100
10^{-3}	72.3	75.7	1.44	91.8	1.82	0.0118	0.0198
10^{-2}	128	53.3	1.34	99.1	1.09	0.0047	0.0110
$\tau = 100$							
0	0.101	100	1.98	-	-	1.00	1.00
10^{-5}	0.200	100	1.98	-	-	0.505	0.505
10^{-4}	1.02	100	1.96	-	-	0.0990	0.100
10^{-3}	5.37	99.5	1.89	-	-	0.0187	0.0198
10^{-2}	10.0	98.8	1.82	-	-	0.0100	0.0110

(Table 2 continued)

^a EC_{50}' , E_{max}' , K_{obs}' and τ_{obs}' denote the corresponding parameter values of EC_{50} , E_{max} , K_{obs} and τ_{obs} in the absence of allosteric modulator.

Table 3: Estimates of EC_{50} , E_{max} and Hill slope for the simulated data in Figures 3a – c. In this example the allosteric modulator causes a ten-fold enhancement in both the affinity ($\alpha = 0.1$) and intrinsic efficacy ($\beta = 10$) of the agonist-receptor complex.

<i>Allosteric Modulator (M)</i>	EC_{50} (μM)	E_{max} (%)	K_{obs} (μM)	τ_{obs}	<i>Hill Slope</i>	$\frac{E_{max} EC_{50}'}{E_{max}' EC_{50}}$ (RA)	$\frac{\tau_{obs} K_{obs}'}{\tau_{obs}' K_{obs}}$ (RA)
$\tau = 1$							
0	5.00	50	10.0	1.00	1.0	1.00	1.00
10^{-6}	0.847	84.6	5.50	5.50	1.0	9.98	10.0
10^{-5}	0.179	90.2	1.82	9.18	1.0	50.4	50.5
10^{-4}	0.0995	90.8	1.09	9.91	1.0	91.2	91.0
10^{-3}	0.0918	90.9	1.01	9.99	1.0	98.9	99.0
$\tau = 10$							
0	0.908	90.9	10.0	10.0	1.0	1.00	1.00
10^{-6}	0.098	98.2	5.50	55.0	1.0	9.99	10.0
10^{-5}	0.0196	98.9	1.82	91.8	1.0	50.3	50.5
10^{-4}	0.0109	99.0	1.09	99.1	1.0	91.0	91.0
10^{-3}	0.0100	99.0	1.01	99.9	1.0	99.1	99.0
$\tau = 100$							
0	0.0990	99.0	-	-	1.0	1.00	1.00
10^{-6}	0.0100	99.8	-	-	1.0	10.0	10.0
10^{-5}	0.0020	99.9	-	-	1.0	50.6	50.5
10^{-4}	0.0011	99.9	-	-	1.0	91.0	91.0
10^{-3}	0.0010	99.9	-	-	1.0	99.1	99.0

(Table 3 continued)

^a EC_{50}' , E_{max}' , K_{obs}' and τ_{obs}' denote the corresponding parameter values of EC_{50} , E_{max} , K_{obs} and τ_{obs} in the absence of allosteric modulator.

Table 4: Estimates of EC_{50} , E_{max} , Hill slope K_{obs} and τ_{obs} for the simulated data in Figures 4a – c.

In this example the allosteric modulator causes ten-fold increase in affinity ($\alpha = 0.1$)
and a ten-fold reduction in intrinsic efficacy ($\beta = 0.1$) of the agonist-receptor complex.

<i>Allosteric Modulator (M)</i>	<i>EC₅₀ (μM)</i>	<i>E_{max} (%)</i>	<i>Hill Slope</i>	<i>K_{obs} (μM)</i>	<i>τ_{obs}</i>	$\frac{E_{max} EC_{50}'}{E_{max} EC_{50}} \alpha$ (RA)	$\frac{\tau_{obs} K_{obs}'}{\tau_{obs} K_{obs}} \alpha$ (RA)
$\tau = 1$							
0	5.00	50	1.0	10.0	1.00	1.00	1.00
10^{-6}	3.55	35.5	1.0	5.50	0.550	1.00	1.00
10^{-5}	1.54	15.4	1.0	1.82	0.182	1.00	1.00
10^{-4}	0.98	9.82	1.0	1.09	0.109	1.00	1.00
10^{-3}	0.92	9.17	1.0	1.01	0.101	1.00	1.00
$\tau = 10$							
0	0.908	90.9	1.0	10.0	10.0	1.00	1.00
10^{-6}	0.847	84.6	1.0	5.50	5.50	1.00	1.00
10^{-5}	0.646	64.5	1.0	1.82	1.82	1.00	1.00
10^{-4}	0.521	52.1	1.0	1.09	1.09	1.00	1.00
10^{-3}	0.502	50.2	1.0	1.01	1.01	1.00	1.00
$\tau = 100$							
0	0.0991	99.0	1.0	-	-	1.00	1.00
10^{-6}	0.098	98.2	1.0	-	-	1.00	1.00
10^{-5}	0.095	94.8	1.0	-	-	1.00	1.00
10^{-4}	0.092	91.6	1.0	-	-	1.00	1.00
10^{-3}	0.091	91.0	1.0	-	-	1.00	1.00

(Table 4 continued)

^a EC_{50}' , E_{max}' , K_{obs}' and τ_{obs}' denote the corresponding parameter values of EC_{50} , E_{max} , K_{obs} and τ_{obs} in the absence of allosteric modulator.

Table 5: Estimates of EC_{50} , E_{max} , Hill slope and RA for the experimental data in Figure 9a.

<i>Gallamine</i> (<i>M</i>)	EC_{50}^a (μM)	E_{max} (% inhibition)	Hill Slope	$\frac{E_{max} EC_{50}'}{E_{max}' EC_{50}}$ (<i>RA</i>)	$\frac{\tau_{obs} K_{obs}'}{\tau_{obs}' K_{obs}}$ (<i>RA</i>)
0	1.26 (5.90 ± 0.16)	54 ± 1.6	0.73 ± 0.11	1.0	1.0
10 ⁻⁶	3.54 (5.45 ± 0.091)	49 ± 1.1	0.78 ± 0.007	0.32 (-0.50 ± 0.19)	0.47 (-0.33 ± 0.11)
3 x 10 ⁻⁶	6.38 (5.20 ± 0.069)	55 ± 1.0	0.95 ± 0.13	0.20 (-0.69 ± 0.14)	0.17 (-0.77 ± 0.17)
10 ⁻⁵	17.1 (4.77 ± 0.053)	51 ± 3.2	0.96 ± 0.19	0.071 (-1.15 ± 0.18)	0.079 (-1.10 ± 0.15)
10 ⁻⁴	35.7 (4.45 ± 0.11)	56 ± 1.9	0.95 ± 0.16	0.037 (-1.44 ± 0.11)	0.029 (-1.54 ± 0.06)
10 ⁻³	73.3 (4.14 ± 0.17)	58 ± 3.2	0.63 ± 0.091	0.020 (-1.70 ± 0.37)	0.018 (-1.76 ± 0.29)

^a The mean negative logarithm ± S.E.M. of each estimate of EC_{50} is indicated in parentheses beneath each EC_{50} estimate.

^b The mean logarithm ± S.E.M. of each estimate of RA is indicated in parentheses beneath each RA estimate.






Figure 1






Figure 2






Figure 3




a*b**c*

Figure 4




Figure 5




Figure 6




Figure 7






Figure 8




Figure 9